IdioVax regulatory update

EMEA's Committee for Orphan Medicinal Products (COMP) issued a positive opinion to grant Orphan Drug designation for CellGenix's IdioVax to treat diffuse large B cell lymphoma (DLBCL). IdioVax, a reco...